VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, unveiled its first in vivo proof-of-concept data and additional in vitro findings for its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The presentation marks a critical milestone for the company as it seeks to advance next-generation antibody-based therapeutics into clinical development.
The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight—a key indicator of tolerability. Importantly, both components of the BiTAC-ADC were required to produce the intended tumor-specific response, underscoring the platform's dual-targeting mechanism. Additional in vitro studies showed the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor, and target multiple cancer cell lines.
These findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates (ADCs) while offering a differentiated safety profile designed to reduce systemic toxicity. If validated in further studies, this could address a major limitation of existing ADCs, which often cause off-target damage and dose-limiting side effects. For patients with aggressive cancers such as breast cancer, the promise of a more tolerable yet equally effective therapy represents a significant step forward.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
The data presented at the World ADC Congress come as the company rapidly advances its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. For investors and industry observers, the results provide early validation of a platform that could differentiate itself in the crowded ADC space. The latest news and updates relating to VRXA are available in the company's newsroom at http://ibn.fm/VRXA.
The announcement was amplified through BillionDollarClub, a specialized communications platform focused on the biggest and brightest companies covered by IBN. As one of 70+ brands within the Dynamic Brand Portfolio @ IBN, BDC delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution. The platform also offers a full array of tailored corporate communications solutions.
For VERAXA, the World ADC Congress presentation is more than a scientific update—it is a signal that the company's BiTAC-ADC platform may be ready for the next stage of development. Success in clinical trials could position VERAXA as a notable player in the evolving landscape of cancer therapeutics, where differentiation in safety and efficacy remains a key competitive advantage.
